scholarly journals Correction: A study towards drug discovery for the management of type 2 diabetes mellitus through inhibition of the carbohydrate-hydrolyzing enzymes α-amylase and α-glucosidase by chalcone derivatives

2019 ◽  
Vol 10 (9) ◽  
pp. 6203-6203 ◽  
Author(s):  
Sónia Rocha ◽  
Adelaide Sousa ◽  
Daniela Ribeiro ◽  
Catarina M. Correia ◽  
Vera L. M. Silva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Discovery ◽  
Chalcone Derivatives ◽  
Hydrolyzing Enzymes

Correction for ‘A study towards drug discovery for the management of type 2 diabetes mellitus through inhibition of the carbohydrate-hydrolyzing enzymes α-amylase and α-glucosidase by chalcone derivatives’ by Sónia Rocha, et al., Food Funct., 2019, DOI: 10.1039/c9fo01298b.

scholarly journals A study towards drug discovery for the management of type 2 diabetes mellitus through inhibition of the carbohydrate-hydrolyzing enzymes α-amylase and α-glucosidase by chalcone derivatives

2019 ◽  
Vol 10 (9) ◽  
pp. 5510-5520 ◽  
Author(s):  
Sónia Rocha ◽  
Adelaide Sousa ◽  
Daniela Ribeiro ◽  
Catarina M. Correia ◽  
Vera L. M. Silva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Discovery ◽  
Competitive Inhibitor ◽  
Therapeutic Drug ◽  
Chalcone Derivatives ◽  
Hydrolyzing Enzymes

Butein, a competitive inhibitor of α-amylase and α-glucosidase enzymes, is a promising therapeutic drug to modulate diabetes mellitus.

scholarly journals Evaluation of the Inhibition of Carbohydrate Hydrolyzing Enzymes, the Antioxidant Activity, and the Polyphenolic Content ofCitrus limettaPeel Extract

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Eduardo Padilla-Camberos ◽  
Estefania Lazcano-Díaz ◽  
José Miguel Flores-Fernandez ◽  
Moses S. Owolabi ◽  
Kirk Allen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Antioxidant Activity ◽  
Type 2 Diabetes Mellitus ◽  
Antioxidant Activities ◽  
Chronic Hyperglycemia ◽  
Hydrolyzing Enzymes ◽  
Dose Dependent ◽  
Citrus Limetta

Type 2 diabetes mellitus is one of the most frequent causes of death in Mexico, characterized by chronic hyperglycemia. One alternative strategy for this metabolic abnormality is inhibiting the enzymes responsible for the metabolism of carbohydrates. We evaluated whether the aqueousCitrus limettapeel extract could inhibit the metabolism of carbohydrates. We found that this extract inhibited primarily the enzymeα-amylase by 49.6% at a concentration of 20 mg/mL and to a lesser extent the enzymeα-glucosidase with an inhibition of 28.2% at the same concentration. This inhibition is likely due to the high polyphenol content in theCitrus limettapeel (19.1 mg GAE/g). Antioxidant activity of theCitrus limettapeel demonstrated dose-dependent antioxidant activity, varying from 6.5% at 1.125 mg/mL to 42.5% at 20 mg/mL. The study of these polyphenolic compounds having both antihyperglycemic and antioxidant activities may provide a new approach to the management of type 2 diabetes mellitus.

scholarly journals GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery

2021 ◽  
Vol 64 (8) ◽  
pp. 4312-4332
Author(s):  
Gabriele Carullo ◽  
Sarah Mazzotta ◽  
Margarita Vega-Holm ◽  
Fernando Iglesias-Guerra ◽  
José Manuel Vega-Pérez ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Discovery

Abstract #1214: Decreasing Hypoglycemia Without Compromising Efficacy in an Aging Type 2 Diabetes Mellitus (T2Dm) Population

2015 ◽  
Vol 21 ◽  
pp. 280-281
Author(s):  
Medha Munshi ◽  
Jasvinder Gill ◽  
Jason Chao ◽  
Elena Nikonova ◽  
Andreas Stuhr ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus
Sign in / Sign up

Export Citation Format

Share Document